GlassScriptPhysician profile
Amy C Wiedower Eble
NPI 1750349098
$2,710.93
in general payments reported to CMS, 2019-2025
27 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $320 · 2021: $715 · 2022: $502 · 2023: $459 · 2024: $222 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $933.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $760.92 | 2019-2023 | Lo Loestrin Fe |
| Evofem Biosciences, INC. | $197.11 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $179.87 | 2019-2025 | |
| Astellas Pharma US INC | $167.11 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $140.90 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Pfizer INC. | $140.67 | 2019-2022 | |
| Davol INC. | $139.35 | 2022-2023 | Arista Ah Flexitip |
| Mayne Pharma Commercial LLC | $131.37 | 2021-2025 | |
| Avion Pharmaceuticals | $119.55 | 2019-2022 | |
| Exeltis, USA INC. | $83.76 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $83.37 | 2019-2024 | Gardasil 9, Gardasil |
| Organon LLC | $71.62 | 2021-2024 | Nexplanon |
| Millicent US INC | $70.23 | 2025 | Intrarosa, Femlyv |
| Aspira Women'S Health INC | $66.50 | 2021 | |
| Biogen, INC. | $55.94 | 2024-2025 | Zurzuvae |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $54.94 | 2021-2022 | |
| Myovant Sciences INC. | $47.28 | 2022 | |
| Ethicon US, LLC | $32.47 | 2020 | |
| Mylan Pharmaceuticals INC. | $28.73 | 2021-2022 | |
| Duchesnay USA Incorporated | $24.49 | 2019 | |
| Shield Therapeutics INC | $20.73 | 2023 | Accrufer |
| Medtronic, INC. | $19.31 | 2022 | |
| Sumitomo Pharma America, INC. | $18.03 | 2025 | Myfembree |
| Molnlycke Health Care US, LLC | $15.88 | 2021 | |
| Allergan, INC. | $15.05 | 2020 | |
| Pharmacosmos Therapeutics INC. | $14.05 | 2023 | Monoferric |
| Agile Therapeutics, INC. | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Wiedower Eble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.